Emerson (EMR) Secures Automation Systems & Services Contract
Zacks Investment Research | Nov 14, 2017 03:55AM ET
Emerson Electric Co. (NYSE:EMR) recently clinched a $40-million automation systems and services contract for Novo Nordisk’s drug manufacturing facility in Clayton, North Carolina. Per the contract, Novo Nordisk’s biggest project, $2-billion plant, will leverage Emerson’s Project Certainty methodologies and automation technologies to fight the global diabetes epidemic.
The Deal
Under the deal, Novo Nordisk (CO:NOVOb) will implement elements of Emerson’s Project Certainty approach, which would trim down project complexity as well as meet its tight-project schedule. The company’s integrated portfolio of automation technologies and services, including Syncade manufacturing execution system and DeltaV distributed control system would help to reduce Novo Nordisk’s project costs as well as accommodate late-stage project changes. This apart, Emerson will also offer smart automation technologies including measurement instrumentation and valves.
Other Notable Contract Wins
Emerson has a solid history of winning valuable contracts in the energy infrastructure field that are conducive to its top-line performance. Some notable contracts secured include a $20-million design-build contract for an automation project from San Francisco Public Utilities Commission and a contract for Biomass-Fueled Plant in United Kingdom. Such contract wins remain a key growth driver for the company.
Existing Business Scenario
Emerson is well-positioned to benefit from global infrastructure growth, as its core businesses hold dominant positions in markets tied to energy efficiency and infrastructure spending. Moreover, environmental regulations are driving the need for new products, adding to its strength. Going forward, Emerson believes telecommunications infrastructure demand will continue to be one of the strongest growth drivers.
Currently, the company remains optimistic about the prospects of Commercial & Residential Solutions segment as it has been witnessing improving trends in the U.S. and Asian construction markets. Also, the company remains bullish on its Automation Solutions segment backed by favorable trends in power and life sciences as well as improving MRO spending by oil and gas customers. Furthermore, the company’s restructuring efforts, undertaken over the past few quarters, are likely to benefit its upcoming results.
This Zacks Rank #3 (Hold) company has returned 5.2% in the past six months, outperforming the industry ’s gain of 2.9%.
Get The News You Want
Despite these positives, prolonged softness in the oil and gas markets has affected both capital spending and operational expenditure of clients, which in turn are hurting Emerson’s operations. The company’s Industrial Automation markets in North America have been extremely challenging and the improvements which Emerson anticipated did not materialize, thereby compunding the challenges.
Stocks to Consider
Some better-ranked stocks from the same space are Columbus McKinnon Corp. (NASDAQ:CMCO) , Kennametal Inc. (NYSE:KMT) and Alamo Group, Inc. (NYSE:ALG) . While Columbus McKinnon and Kennametal sport a Zacks Rank #1 (Strong Buy), Alamo Group carries a Zacks Rank #2 (Buy). You can see .
Columbus McKinnon has surpassed estimates thrice in the trailing four quarters, with an average positive earnings surprise of 15.4%.
Kennametal has outpaced estimates thrice in the preceding four quarters, with an average earnings surprise of 20.6%.
Alamo Group has surpassed estimates twice in the trailing four quarters, with an average positive earnings surprise of 6.1%.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.